The agreement has an initial term until March 31, 2029 and no further details on the financial terms of the deal are being disclosed
Enhanced collaboration under the Memorandum of Cooperation (MoC) between India and Japan in medical product regulations
KIMS already have a multi-specialty hospital and gastro unit at Vizag
Acquisition to expand Lilly's immunology pipeline with oral integrin therapies
The My Green Lab Certification is the gold standard for laboratory sustainability practices worldwide
Globally, colorectal cancer impacts 1.9 million people each year, standing as a leading cause of cancer mortality
Olverembatinib, a novel drug developed by Ascentage Pharma with support from the National Major New Drug Development program
Acquisition provides Ligand with the royalty rights to QARZIBA, a highly differentiated, commercial oncology drug marketed in 35 countries by global pharmaceutical company Recordati S.p.A.
The academy has secured partnerships with 15 esteemed hospitals
NCIL was listed at Rs. 171 at an upper circuit premium of 90% over the fixed price band of Rs. 90
Subscribe To Our Newsletter & Stay Updated
